Gesellschaftsrecht / M&A

Kapitalmarkt

Arbeitsrecht und Vergütung für Führungskräfte

Finanzierungen und Anlageprodukte

Steuern

Galderma-webnews

Homburger News

Homburger and Galderma

On March 13, 2024, Galderma Group AG (Galderma), the pure-play dermatology category leader, announced the launch of its Initial Public Offering (Offering) on the SIX Swiss Exchange. The Offering consists of up to 40,453,467 newly issued shares and up to 276,909 existing shares sold by one of its shareholders, Sunshine SwissCo AG (EQT), with an over-allotment option of up to 6,109,158 existing registered shares granted by EQT together with the Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd.
Based on the offer price range between CHF 49 and CHF 53 resulting in an offer size of approximately CHF 2.3 billion (assuming the over-allotment option is exercised in full), the implied market capitalization of Galderma is estimated between CHF 11.8 billion and CHF 12.6 billion. The listing and the first day of trading are expected to take place on March 22, 2024. Galderma will be included in the Swiss Performance Index (SPI).
Homburger acts as issuer&#8217;s, selling shareholder&#8217;s and transaction counsel to Galderma and EQT. The team is led by Frank Gerhard, Lorenzo Togni and Margrit Marti (all Capital Markets; Corporate/M&amp;A) and comprises Micha Fankhauser, Estelle Piccard, Jasmin Künzle, Héloïse de Jamblinne, Lucas Forrer and Daniel Wenzinger (all Capital Markets; Corporate/M&amp;A), Andreas Müller and Anna Peter (Employment and Executive Compensation), Jürg Frick, Stefan Bindschedler, Daniel Junginger and Sarah Fasel (all Financing and Investment Products), Stefan Oesterhelt and Laetitia Fracheboud (both Tax).

Homburger advises Galderma on its IPO on SIX Swiss Exchange

PK24_Newsmeldung-web-640x140

Drei neue Partner für Homburger

Wir heissen Anna Peter, Margrit Marti und Miguel Sogo in unserer Partnerschaft herzlich willkommen. <a href="https://www.homburger.ch/de/home/welcome?utm_source=news-website&amp;utm_medium=newsmeldung-de&amp;utm_campaign=welcome-2024&amp;utm_id=welcome&amp;utm_content=de">Zum Porträt</a>

Zwei neue Partnerinnen und ein neuer Partner für Homburger

Healthcare / Life Sciences

Tolremo-web-640x140

Homburger and TOLREMO therapeutics

On September 20, 2023, TOLREMO therapeutics AG announced that it has completed its Series A financing, bringing the total amount raised to USD 39 m (CHF 34.1 m). BioMedPartners AG led the round with participation from a new investor, Pierre Fabre Invest, as well as existing investors.
TOLREMO&#8217;s mission is to stop non-genetic cancer drug resistance as it emerges by dismantling cancer&#8217;s earliest defenses to targeted therapies, thus surmounting a universal challenge for current and future targeted treatments.
The Homburger team was led by Dieter Gericke and Margrit Marti and comprised Francesco Bernasconi, Stefan Luginbühl, Thierry Burckhardt and Claudine Schär (all Corporate / M&amp;A; Healthcare / Life Sciences) as well as Stefan Oesterhelt (Tax).

Homburger advised TOLREMO therapeutics AG on the extension of its Series A financing round

Margrit
Marti

Homburger advises Galderma on its IPO on SIX Swiss Exchange

Zwei neue Partnerinnen und ein neuer Partner für Homburger

Homburger advised TOLREMO therapeutics AG on the extension of its Series A financing round

Nutzbarmachung des neuen Aktienrechts für Private Equity und Venture Capital

ESG reporting and due diligence obligations introduced in Switzerland

KISS und SAFE: Neue Strukturen für Venture Investments

Join the Team

Margrit Marti

Karriere

Sprachen

Zulassung

Teams

MargritMarti

Homburger advises Galderma on its IPO on SIX Swiss Exchange

Zwei neue Partnerinnen und ein neuer Partner für Homburger

Homburger advised TOLREMO therapeutics AG on the extension of its Series A financing round

Nutzbarmachung des neuen Aktienrechts für Private Equity und Venture Capital

ESG reporting and due diligence obligations introduced in Switzerland

KISS und SAFE: Neue Strukturen für Venture Investments

Join the Team

Margrit Marti

Karriere

Sprachen

Zulassung

Teams

Margrit
Marti